工程化T細胞市場－全球產業規模、佔有率、趨勢、機會、預測：按類型、應用、最終用戶、地區和競爭格局分類，2021-2031年

全球基因改造 T 細胞市場預計將從 2025 年的 62.3 億美元大幅成長至 2031 年的 127.4 億美元，複合年成長率將達到 12.66%。

基因改造T細胞是一種創新免疫療法，它透過基因工程改造T淋巴細胞，使其能夠特異性識別並清除癌細胞。推動該市場擴張的關鍵因素包括骨髓惡性腫瘤率的上升、此類治療方法監管核准的穩定成長，以及對臨床研發的持續大量投入。這些因素，即使不依賴特定的技術進步，也持續加速新治療方法的研發，並支撐著整個產業的成長。

儘管前景光明，但高昂的製造成本和複雜的內部生產物流要求是限制市場整體成長的主要障礙。這些運作挑戰往往導致治療成本上升，並限制患者獲得治療的機會。儘管如此，該領域仍保持強勁的發展勢頭。美國基因與細胞治療學會預測，到2025年，全球將有超過3,200項基因、細胞和RNA療法的臨床試驗正在進行中。如此龐大的研發管線凸顯了該產業為克服研發障礙和拓展治療選擇而持續做出的努力。

市場促進因素

全球基因改造T細胞市場的主要驅動力是骨髓惡性腫瘤和固態腫瘤發生率的不斷上升。由於傳統化療往往無法在難治性病例中達到持續緩解，因此對精準免疫療法的臨床需求日益成長。令人擔憂的診斷預測進一步凸顯了這項迫切需求。美國癌症協會發布的《2025年癌症事實與數據》報告預測，美國每年新增癌症病例數將首次超過200萬例。因此，醫療系統正日益重視採用先進的細胞療法，以彌補有效患者照護日益擴大的差距。

同時，監管機構加快核准流程並給予支持性認定，顯著推動了市場成長，這些治療方法的商業性前景正在迅速擴大。監管機構正在簡化審查流程，促進新參與企業穩定增加，並擴大現有產品的適應症。例如，Fierce Pharma在2026年1月通報稱，美國食品藥物管理局（FDA）在2025年核准了五種新的細胞和基因療法。監管支持與市場價值和產業成長直接相關，關鍵產品的強勁表現證明了這一點。百時美施貴寶公司在2025年10月報告稱，其CAR-T療法Breyanzi的季度銷售額達到3.59億美元，年增58%。

市場挑戰

阻礙基因改造T細胞市場擴張的最大障礙在於其內部生產模式的高成本及其固有的物流複雜性。與傳統的大規模生產藥物不同，自體療法需要個人化的「靜脈到靜脈」供應鏈，包括採集、基因改造和重新輸注患者自身的細胞。這種客製化流程勞動密集，難以高效規模化生產，且極易受到供應鏈中斷的影響，使得製造商無法實現降低單位成本所需的規模經濟。

這些營運效率低下迫使製造商設定高價，進而限制了保險報銷，並縮小了患者獲得專科治療中心的機會。由於無法有效擴大生產規模，市場商業性成功集中在少數幾種克服了這些障礙的已通過核准治療方法。根據再生醫學聯盟2025年的數據，全球約75%的市場收入將由不到10種市售產品創造，這清楚地表明，生產複雜性如何直接限制了市場的廣泛商業化和盈利能力。

市場趨勢

關鍵市場趨勢之一是基因改造T細胞在自體免疫疾病領域的應用日益廣泛。這標誌著治療領域正從傳統的腫瘤治療轉向其他治療方式。研發人員正策略性地利用嵌合體抗原受體（CAR）來清除自體反應性B細胞，旨在實現全身性紅斑性狼瘡和僵人症候群等疾病的持續緩解。在非惡性疾病適應症中觀察到的顯著臨床療效也支持了這一治療領域的拓展，凸顯了重置免疫系統的潛力。例如，Fierce Biotech公司於2025年12月報告稱，在其核准mivocabtadiene autolthol的臨床試驗中，81%的患者在主要終點——步行測試中表現出具有臨床意義的改善。這正在加速整個產業向免疫學領域的策略轉型，並創造一條清晰的新收入來源。

同時，業界正加速向異體「現成」T細胞療法轉型，旨在規避內部藥物生產固有的規模化限制。透過利用供體來源的細胞，製造商正在開發可隨時使用的治療方法避免了漫長的靜脈輸注間隔，並顯著降低了生產成本。這些異體療法目前已在一些疑難病例中展現出具競爭力的臨床療效。 2025年6月，Allogene Therapeutics公司公佈了更新的I期臨床試驗數據，顯示其異體候選藥物ALLO-316在CD70高表達的腎細胞癌患者中達到了31%的確認緩解率。這些結果支持了該領域致力於提供可擴展、經濟高效且無需依賴個人化生產流程的免疫療法的決心。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球工程化T細胞市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 依類型（嵌合體抗原受體、T細胞受體、腫瘤浸潤淋巴細胞）
  • 依應用領域（乳癌、大腸癌、白血病、肺癌、惡性黑色素瘤）
  • 按最終用戶（癌症研究中心、診所、醫院等）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美工程化T細胞市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲工程化T細胞市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區工程化T細胞市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲工程化T細胞市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲工程化T細胞市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章：全球工程化T細胞市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Novartis AG
• Gilead Sciences, Inc.
• Bristol-Myers Squibb Company
• Legend Biotech Corporation
• Bluebird Bio, Inc.
• Cellares Corporation
• Kite Pharma, Inc.
• Allogene Therapeutics, Inc.
• Adaptimmune Therapeutics plc
• Servier Laboratories Ltd.

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Engineered T Cells Market is projected to expand significantly, growing from USD 6.23 Billion in 2025 to USD 12.74 Billion by 2031, demonstrating a compound annual growth rate of 12.66%. Engineered T cells represent an innovative form of immunotherapy where T lymphocytes are genetically modified to specifically identify and eliminate cancer cells. Key factors propelling this market expansion include the increasing incidence of hematological malignancies, a steady rise in regulatory approvals for these treatments, and substantial ongoing investments in clinical research, which consistently foster the development of new therapies and support overall sectoral growth independent of specific technological advancements.

Despite the positive outlook, a major hurdle for broader market growth is the considerable manufacturing cost and intricate logistical demands associated with autologous production processes. These operational challenges frequently lead to high treatment prices and limit patient access. Nevertheless, the sector maintains robust momentum, as evidenced by over 3,200 active global trials for gene, cell, and RNA therapies in 2025, according to the American Society of Gene & Cell Therapy. This extensive pipeline underscores the industry's continued dedication to overcoming development barriers and expanding therapeutic options.

Market Driver

The primary impetus for the Global Engineered T Cells Market stems from the escalating prevalence of both hematological malignancies and solid tumors. As traditional chemotherapies often prove ineffective in achieving sustained remissions for refractory cases, the clinical demand for precise immunotherapies is intensifying. This critical need is underscored by alarming diagnostic projections, with the American Cancer Society's 'Cancer Facts & Figures 2025' report forecasting over 2 million new cancer cases in the United States in a single year for the first time. Consequently, healthcare systems are increasingly prioritizing the adoption of advanced cellular therapies to address this growing gap in effective patient care.

Simultaneously, the market is significantly bolstered by accelerated regulatory approvals and supportive designation pathways, which are rapidly expanding the commercial landscape for these treatments. Regulatory bodies are streamlining review processes, facilitating a steady stream of new market entrants and broader indications for existing products. For instance, Fierce Pharma reported in January 2026 that the US FDA approved five new cell and gene therapies in 2025. This regulatory support directly translates into substantial market value and industrial growth, exemplified by the strong performance of leading assets; Bristol Myers Squibb reported in October 2025 that sales for its CAR-T therapy Breyanzi surged by 58% year-over-year to reach $359 million for the quarter.

Market Challenge

The most significant obstacle hindering the expansion of the engineered T-cell market is the exorbitant cost and inherent logistical complexity of autologous manufacturing models. Unlike conventional mass-produced pharmaceuticals, autologous therapies necessitate a personalized "vein-to-vein" supply chain, involving the harvesting, genetic modification, and re-infusion of a patient's own cells. This customized process is labor-intensive, difficult to scale efficiently, and highly susceptible to supply chain disruptions, preventing manufacturers from achieving the economies of scale essential for reducing unit costs.

These operational inefficiencies consequently compel manufacturers to impose high price points, which, in turn, limit reimbursement coverage and restrict patient access to specialized treatment centers. The inability to scale production efficiently has created a market where commercial success is largely concentrated among a select few approved therapies that have successfully navigated these hurdles. Data from the Alliance for Regenerative Medicine in 2025 indicates that approximately 75% of the global sector's revenue was generated by fewer than ten commercially available products, clearly demonstrating how manufacturing complexity directly constrains the broader commercialization and revenue potential of the market.

Market Trends

A significant market trend involves the expanding application of engineered T cells into autoimmune diseases, representing a transformative shift beyond their traditional oncology focus. Developers are strategically employing chimeric antigen receptors to deplete autoreactive B cells, with the aim of achieving durable remission in conditions such as systemic lupus erythematosus and stiff person syndrome. This therapeutic expansion is reinforced by compelling clinical efficacy observed in non-malignant indications, confirming the potential for an immune system reset. For example, Fierce Biotech reported in December 2025 that a registrational trial for mivocabtagene autoleucel showed 81% of patients achieving a clinically meaningful reduction in the primary walking test endpoint, thereby driving a strategic industry pivot towards immunology and creating a distinct new revenue stream.

Concurrently, the industry is witnessing an accelerated transition towards allogeneic "off-the-shelf" T cell therapies, designed to circumvent the scalability limitations inherent in autologous manufacturing. By utilizing donor-derived cells, manufacturers are developing readily available treatments that eliminate the protracted vein-to-vein lag times and substantially reduce production expenses. This allogeneic modality is now demonstrating competitive clinical promise in challenging treatment scenarios. Allogene Therapeutics, in June 2025, released updated Phase 1 data showing that its allogeneic candidate ALLO-316 achieved a 31% confirmed response rate in renal cell carcinoma patients with high CD70 expression. These milestones underscore the sector's commitment to delivering scalable, cost-effective immunotherapies independent of personalized manufacturing processes.

Key Market Players

• Novartis AG
• Gilead Sciences, Inc.
• Bristol-Myers Squibb Company
• Legend Biotech Corporation
• Bluebird Bio, Inc.
• Cellares Corporation
• Kite Pharma, Inc.
• Allogene Therapeutics, Inc.
• Adaptimmune Therapeutics plc
• Servier Laboratories Ltd.

Report Scope

In this report, the Global Engineered T Cells Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Engineered T Cells Market, By Type

• Chimeric Antigen Receptor
• T Cell Receptor
• Tumor-Infiltrating Lymphocytes

Engineered T Cells Market, By Application

• Breast Cancer
• Colorectal Cancer
• Leukemia
• Lung Cancer
• Melanoma

Engineered T Cells Market, By End-User

• Cancer Research Centers
• Clinics
• Hospitals
• Others

Engineered T Cells Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Engineered T Cells Market.

Available Customizations:

Global Engineered T Cells Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Engineered T Cells Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Chimeric Antigen Receptor, T Cell Receptor, Tumor-Infiltrating Lymphocytes)
  • 5.2.2. By Application (Breast Cancer, Colorectal Cancer, Leukemia, Lung Cancer, Melanoma)
  • 5.2.3. By End-User (Cancer Research Centers, Clinics, Hospitals, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Engineered T Cells Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Application
  • 6.2.3. By End-User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Engineered T Cells Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By End-User
  • 6.3.2. Canada Engineered T Cells Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By End-User
  • 6.3.3. Mexico Engineered T Cells Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By End-User

7. Europe Engineered T Cells Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Application
  • 7.2.3. By End-User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Engineered T Cells Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By End-User
  • 7.3.2. France Engineered T Cells Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By End-User
  • 7.3.3. United Kingdom Engineered T Cells Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By End-User
  • 7.3.4. Italy Engineered T Cells Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By End-User
  • 7.3.5. Spain Engineered T Cells Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By End-User

8. Asia Pacific Engineered T Cells Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Application
  • 8.2.3. By End-User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Engineered T Cells Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By End-User
  • 8.3.2. India Engineered T Cells Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By End-User
  • 8.3.3. Japan Engineered T Cells Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By End-User
  • 8.3.4. South Korea Engineered T Cells Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By End-User
  • 8.3.5. Australia Engineered T Cells Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By End-User

9. Middle East & Africa Engineered T Cells Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Application
  • 9.2.3. By End-User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Engineered T Cells Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By End-User
  • 9.3.2. UAE Engineered T Cells Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By End-User
  • 9.3.3. South Africa Engineered T Cells Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By End-User

10. South America Engineered T Cells Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Application
  • 10.2.3. By End-User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Engineered T Cells Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By End-User
  • 10.3.2. Colombia Engineered T Cells Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By End-User
  • 10.3.3. Argentina Engineered T Cells Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By End-User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Engineered T Cells Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Novartis AG
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Gilead Sciences, Inc.
• 15.3. Bristol-Myers Squibb Company
• 15.4. Legend Biotech Corporation
• 15.5. Bluebird Bio, Inc.
• 15.6. Cellares Corporation
• 15.7. Kite Pharma, Inc.
• 15.8. Allogene Therapeutics, Inc.
• 15.9. Adaptimmune Therapeutics plc
• 15.10. Servier Laboratories Ltd.

16. Strategic Recommendations

17. About Us & Disclaimer